Canadian Firm Explores Potential Of Nasal Spray In COVID-19 Prevention
Dr Gilly Regev, CEO of the anti-infectives-focused firm, SaNOtize Research & Development Corp, remains confident of the effectiveness of the firm’s nitric oxide nasal spray against evolving variants of SARS-CoV-2 and expects to progress plans for a “prevention” trial in the US.
You may also be interested in...
Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.
Canada-based biotech firm SaNOtize and Lupin battle it out in court over alleged breach of confidentiality and copyright infringement in a case concerning their nitric oxide nasal spray for COVID-19.
Glenmark's partnered nitric oxide nasal spray for COVID-19 debuts in India at about $11, with the firm spotlighting the reduction in viral load with the product and potential to cut the chain of transmission. But more competition appears to be in the wings.